Sign in or create an account to add this stock to your watchlist.
About Immune Design (NASDAQ:IMDZ)
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMDZ
CUSIPN/A
Phone206-682-0645
Debt
Debt-to-Equity RatioN/A
Current Ratio21.18
Quick Ratio21.08
Price-To-Earnings
Trailing P/E Ratio-2.66
Forward P/E Ratio-3.66
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.20 million
Price / Sales31.08
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book1.60
Profitability
EPS (Most Recent Fiscal Year)($1.75)
Net Income$-51,860,000.00
Net Margins-2,352.98%
Return on Equity-52.00%
Return on Assets-45.88%
Miscellaneous
Employees56
Outstanding Shares48,130,000
Immune Design (NASDAQ:IMDZ) Frequently Asked Questions
What is Immune Design's stock symbol?
Immune Design trades on the NASDAQ under the ticker symbol "IMDZ."
How were Immune Design's earnings last quarter?
Immune Design Corp (NASDAQ:IMDZ) posted its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($0.28) EPS for the quarter, topping the Zacks' consensus estimate of ($0.29) by $0.01. The biotechnology company had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.83 million. Immune Design had a negative return on equity of 52.00% and a negative net margin of 2,352.98%. View Immune Design's Earnings History.
When is Immune Design's next earnings date?
What price target have analysts set for IMDZ?
4 brokerages have issued twelve-month price objectives for Immune Design's shares. Their forecasts range from $8.00 to $20.00. On average, they expect Immune Design's stock price to reach $12.6667 in the next twelve months. View Analyst Ratings for Immune Design.
Who are some of Immune Design's key competitors?
Some companies that are related to Immune Design include Kiniksa Pharmaceuticals Cl A (KNSA), Collegium Pharmaceutical (COLL), Rocket Pharmaceuticals (RCKT), Dova Pharmaceuticals (DOVA), AMAG Pharmaceuticals (AMAG), Theratechnologies (THERF), CymaBay Therapeutics (CBAY), NuCana (NCNA), ANI Pharmaceuticals Inc Common Stock (ANIP), Amphastar Pharmaceuticals (AMPH), Abeona Therapeutics (ABEO), Inflarx (IFRX), Urogen Pharma (URGN), Vectura Group (VEGPF) and Geron (GERN).
Who are Immune Design's key executives?
Immune Design's management team includes the folowing people:
- Dr. Carlos V. Paya, CEO, Pres & Director (Age 59)
- Mr. Stephen R. Brady, Exec. VP of Strategy & Fin. (Age 48)
- Dr. Jan Henrik Ter Meulen, Chief Scientific Officer (Age 55)
- Mr. Christopher Whitmore CPA, VP of Fin. & Admin.
- Dr. Wayne R. Gombotz, Chief Devel. Officer (Age 59)
Has Immune Design been receiving favorable news coverage?
Press coverage about IMDZ stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Immune Design earned a media sentiment score of 0.13 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.80 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Immune Design's major shareholders?
Immune Design's stock is owned by a number of of institutional and retail investors. Top institutional investors include BVF Inc. IL (8.53%), BlackRock Inc. (3.98%), JPMorgan Chase & Co. (1.75%), Dimensional Fund Advisors LP (0.40%) and DRW Securities LLC (0.08%). Company insiders that own Immune Design stock include Carlos V Paya, Franklin M Berger, Group L P Column, Leo Guthart, Lewis W Coleman, Meulen Jan Henrik Ter, Peter Svennilson, Sergey Yurasov, Stephen R Brady and Wayne Gombotz. View Institutional Ownership Trends for Immune Design.
Which major investors are selling Immune Design stock?
IMDZ stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have sold Immune Design company stock in the last year include Carlos V Paya, Meulen Jan Henrik Ter, Sergey Yurasov, Stephen R Brady and Wayne Gombotz. View Insider Buying and Selling for Immune Design.
Which major investors are buying Immune Design stock?
IMDZ stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Dimensional Fund Advisors LP, BlackRock Inc. and DRW Securities LLC. Company insiders that have bought Immune Design stock in the last two years include Franklin M Berger, Group L P Column, Leo Guthart, Lewis W Coleman, Peter Svennilson and Stephen R Brady. View Insider Buying and Selling for Immune Design.
How do I buy shares of Immune Design?
Shares of IMDZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immune Design's stock price today?
One share of IMDZ stock can currently be purchased for approximately $4.65.
How big of a company is Immune Design?
Immune Design has a market capitalization of $223.78 million and generates $7.20 million in revenue each year. The biotechnology company earns $-51,860,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Immune Design employs 56 workers across the globe.
How can I contact Immune Design?
Immune Design's mailing address is 1616 EASTLAKE AVENUE EAST SUITE 310, SEATTLE WA, 98102. The biotechnology company can be reached via phone at 206-682-0645 or via email at [email protected]
MarketBeat Community Rating for Immune Design (IMDZ)
MarketBeat's community ratings are surveys of what our community members think about Immune Design and other stocks. Vote "Outperform" if you believe IMDZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMDZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
Immune Design (NASDAQ:IMDZ) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Immune Design in the last 12 months. Their average twelve-month price target is $12.6667, suggesting that the stock has a possible upside of 172.40%. The high price target for IMDZ is $20.00 and the low price target for IMDZ is $8.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $12.6667 | $12.6667 | $12.6667 | $16.00 |
| Price Target Upside: | 172.40% upside | 224.79% upside | 224.79% upside | 332.43% upside |
Immune Design (NASDAQ:IMDZ) Consensus Price Target History
Immune Design (NASDAQ:IMDZ) Analyst Ratings History
Show:
(Data available from 6/17/2016 forward)
Immune Design (NASDAQ:IMDZ) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Immune Design (NASDAQ IMDZ) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 18.10%
Institutional Ownership Percentage: 50.70%
Immune Design (NASDAQ IMDZ) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/8/2018 | Leo Guthart | Major Shareholder | Buy | 20,000 | $3.90 | $78,000.00 | |  |
| 1/5/2018 | Carlos V Paya | CEO | Sell | 7,970 | $4.17 | $33,234.90 | 114,560 | |
| 1/5/2018 | Meulen Jan Henrik Ter | Insider | Sell | 1,986 | $4.17 | $8,281.62 | 41,020 | |
| 1/5/2018 | Stephen R Brady | EVP | Sell | 3,328 | $4.17 | $13,877.76 | 50,490 | |
| 1/4/2018 | Sergey Yurasov | VP | Sell | 675 | $4.17 | $2,814.75 | 28,000 | |
| 11/2/2017 | Lewis W Coleman | Director | Buy | 50,000 | $4.50 | $225,000.00 | | |
| 10/30/2017 | Franklin M Berger | Director | Buy | 25,000 | $4.58 | $114,500.00 | 75,000 | |
| 10/27/2017 | Leo Guthart | Major Shareholder | Buy | 2,439,000 | $4.10 | $9,999,900.00 | | |
| 10/27/2017 | Peter Svennilson | Director | Buy | 2,681,000 | $4.10 | $10,992,100.00 | | |
| 10/25/2017 | Franklin M Berger | Director | Buy | 25,000 | $4.26 | $106,500.00 | 50,000 | |
| 10/24/2017 | Leo Guthart | Major Shareholder | Buy | 60,000 | $4.65 | $279,000.00 | | |
| 10/19/2017 | Leo Guthart | Major Shareholder | Buy | 10,000 | $6.09 | $60,900.00 | | |
| 9/18/2017 | Leo Guthart | Major Shareholder | Buy | 10,000 | $9.70 | $97,000.00 | | |
| 8/1/2017 | Wayne Gombotz | Insider | Sell | 10,000 | $11.43 | $114,300.00 | 33,054 | |
| 7/11/2017 | Lewis W Coleman | Director | Buy | 12,000 | $9.05 | $108,600.00 | 40,000 | |
| 7/10/2017 | Lewis W Coleman | Director | Buy | 10,000 | $9.00 | $90,000.00 | 40,000 | |
| 7/7/2017 | Lewis W Coleman | Director | Buy | 8,000 | $9.27 | $74,160.00 | 40,000 | |
| 1/4/2017 | Carlos V Paya | Insider | Sell | 3,940 | $5.35 | $21,079.00 | 72,000 | |
| 1/4/2017 | Stephen R Brady | EVP | Sell | 1,642 | $5.35 | $8,784.70 | 32,132 | |
| 12/22/2016 | Lewis W Coleman | Director | Sell | 10,000 | $6.20 | $62,000.00 | 40,000 | |
| 12/16/2016 | Franklin M Berger | Director | Sell | 50,000 | $6.55 | $327,500.00 | 25,000 | |
| 9/20/2016 | Group L P Column | Major Shareholder | Buy | 800,000 | $6.25 | $5,000,000.00 | | |
| 9/20/2016 | Lewis W Coleman | Director | Buy | 40,000 | $6.25 | $250,000.00 | 50,000 | |
| 7/15/2016 | Stephen R Brady | EVP | Buy | 1,500 | $6.84 | $10,260.00 | 17,132 | |
| 11/23/2015 | Wayne Gombotz | insider | Sell | 5,000 | $20.00 | $100,000.00 | 34 | |
| 9/14/2015 | Wayne Gombotz | insider | Sell | 5,000 | $16.19 | $80,950.00 | 34 | |
| 8/25/2015 | Lewis W Coleman | Director | Buy | 3,000 | $14.50 | $43,500.00 | 10,000 | |
| 5/12/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 177,607 | $21.60 | $3,836,311.20 | | |
| 4/24/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 82,892 | $26.81 | $2,222,334.52 | | |
| 4/21/2015 | Franklin M Berger | Director | Buy | 25,000 | $26.50 | $662,500.00 | | |
| 4/21/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 45,820 | $26.51 | $1,214,688.20 | | |
| 4/16/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 53,914 | $28.23 | $1,521,992.22 | | |
| 4/7/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 7,495 | $26.72 | $200,266.40 | | |
| 3/25/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 18,156 | $27.64 | $501,831.84 | | |
| 3/23/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 44,464 | $27.52 | $1,223,649.28 | | |
| 3/18/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 50,309 | $26.09 | $1,312,561.81 | | |
| 3/12/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 129,342 | $24.94 | $3,225,789.48 | | |
| 3/9/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 39,446 | $25.45 | $1,003,900.70 | | |
| 7/29/2014 | Alta Partners Viii, L.P. | Major Shareholder | Buy | 299,559 | $12.00 | $3,594,708.00 | | |
| 7/29/2014 | Franklin M Berger | Director | Buy | 50,000 | $12.00 | $600,000.00 | | |
(Data available from 1/1/2013 forward)
Immune Design (NASDAQ IMDZ) News Headlines
| Source: |
|
Immune Design (NASDAQ:IMDZ) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Immune Design (NASDAQ:IMDZ) Income Statement, Balance Sheet and Cash Flow Statement
Immune Design (NASDAQ IMDZ) Stock Chart for Sunday, June, 17, 2018
Loading chart…
